SFRP4 and gastric cancer: We then exploited the secreted nature of the SFRP4 protein to develop an ELISA-based assay (SFRP4 ratio) which, when used in conjunction with existing clinical variables, is able to predict disease recurrence in GC patients after curative resection with a high degree of accuracy.